Authored By: Sarah
14 Aug 2024

 Non-Small Cell Lung Cancer Drugs Market Size to grow by USD 21061.2 million between 2024-2028

According to a research report “ Non-Small Cell Lung Cancer Drugs Market” by Type (Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma) Product (Biologics, Small molecule targeted therapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 21061.2 million, at a CAGR of 10.87% during the forecast period. The rising incidence of Non-Small Cell Lung Cancer (NSCLC) in North America necessitates increased focus on awareness, early detection, and effective treatment strategies. In the US, the American Cancer Society anticipates 238,340 new NSCLC cases in 2023. In Canada, the Canadian Cancer Society reports 30,000 diagnoses in 2022, accounting for 13% of all new cancer cases. Lung cancer is the most frequently diagnosed cancer and leading cause of cancer-related deaths in Canada, as per Statistics Canada's January 2022 report. These statistics underscore the significant burden of NSCLC in North America, emphasizing the importance of implementing comprehensive intervention measures to address this critical health concern..

Browse market data tables, figures, and in-depth TOC on “Non-Small Cell Lung Cancer Drugs Market” by Type (Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma) Product (Biologics, Small molecule targeted therapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

By Type, the Adenocarcinoma segment is projected to dominate the market size in 2024

Adenocarcinoma is a type of malignant tumor that originates in the glandular epithelium, accounting for the majority of lung cancer cases. This disease arises when normal cellular growth is disrupted, leading to uncontrolled cell division and the formation of tumors. Several risk factors contribute to the development of adenocarcinoma, primarily including tobacco use, exposure to toxins, and previous radiation therapy. Smoking is a leading cause of adenocarcinoma, with tobacco use contributing to approximately 85% of all lung cancer cases. Harmful toxins found in the home or work environment can also increase the risk of developing adenocarcinoma. Previous radiation therapy, particularly in the chest area, has been identified as a significant risk factor, increasing the likelihood of adenocarcinoma by up to 20%. It is crucial for individuals to minimize exposure to these risk factors to reduce the likelihood of developing adenocarcinoma and other related diseases.

By Product, Biologics  segment is expected to hold the largest market size for the year 2024

The Non-Small Cell Lung Cancer (NSCLC) Drugs Market is experiencing significant growth due to the rising prevalence of this disease and the introduction of innovative biologic treatments. Biologics, such as KEYTRUDA, TECENTRIQ, IMFINZI, and OPDIVO, which are used in immunotherapy, are driving market expansion. The adoption of these advanced treatments for NSCLC is increasing, fueled by their proven efficacy and improved patient outcomes. The biologics segment is projected to exhibit robust growth during the forecast period, with a strong drug pipeline set to launch first-line treatments for NSCLC patients. Notable additions to this pipeline include immune checkpoint inhibitors like cemiplimab and tislelizumab, as well as combination therapies such as ipilimumab with tremelimumab, IMFINZI with tremelimumab, pembrolizumab with ipilimumab, IMFINZI with chemotherapy, pemetrexed and carboplatin, and cemiplimab with ipilimumab. These advancements in immunotherapy are enhancing overall patient survival, further bolstering market growth.

North America is forecasted to hold the largest market size by region in 2024

The Non-Small Cell Lung Cancer (NSCLC) Drugs Market represents a significant business opportunity due to the increasing prevalence of this disease and the continuous development of innovative therapeutic solutions. Key players in this market are investing heavily in research and development to launch effective treatments, including targeted therapies and immunotherapies. The market is expected to grow robustly in the coming years, driven by rising demand, technological advancements, and regulatory approvals.

The Non-Small Cell Lung Cancer Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • DeuterOncology NV
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Innovent Biologics Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Merck KGaA
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • PharmaMar SA
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Title: Non-Small Cell Lung Cancer Drugs Market: Current Landscape and Future Prospects Non-Small Cell Lung Cancer (NSCLC) is a leading cause of morbidity and mortality worldwide, with tobacco consumption, air pollution, asbestos exposure, and a history of smoking being major risk factors. The NSCLC drugs market encompasses a wide range of treatments, including immunotherapy, targeted therapy, radiation therapy, chemotherapy, and biologics. Drug stores and hospitals are key players in the distribution of NSCLC drugs. With the ongoing COVID-19 pandemic, social distancing measures have led to an increase in teleconsultations and home delivery services for medications. Roche, a leading pharmaceutical company, offers several NSCLC drugs such as Avastin, Tarceva, and Alecensa. Arsenic trioxide, an older treatment for NSCLC, has shown promise in combination with other therapies. Advancements in technology, such as CT scans and deep learning systems, have improved diagnosis and personalized treatment plans. Massachusetts General Hospital's pipeline includes Mitotane, a mitotic inhibitor, and Erbitux, a monoclonal antibody. Smoking behaviors and environmental factors continue to fuel the need for new treatments. Small molecules like Alkylating Agents and Multi-kinase Inhibitors are under investigation for their potential in NSCLC treatment. Biologics, such as those based on monoclonal antibodies and RNA interference, offer targeted therapy options. In conclusion, the NSCLC drugs market is constantly evolving, with ongoing research and development focusing on improving patient outcomes and addressing the unmet needs of this patient population.

Market Research Overview

Non-Small Cell Lung Cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The treatment landscape for NSCLC includes various modalities such as surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Reimbursement policies for NSCLC drugs vary across channels, including online pharmacies, retail pharmacies, drug stores, and hospitals. The history of smoking, tobacco consumption, and polluted air are significant risk factors for NSCLC. Roche's Targeted Therapy, Arsenic Trioxide, and Asbestos exposure are some historical treatments for NSCLC. Current treatments include OSE Immunotherapeutics' Anti-TIM-3 antibody, BeyondSpring Pharmaceuticals' Plinabulin, Xcovery's X396, and Hoffmann-La Roche's Alecensa. Novartis Pharmaceuticals, Rain Therapeutics, and Moderna are developing immunotherapy and messenger RNA (mRNA) drugs. Daiichi Sankyo offers Surgery, Oral drugs, and Combination Therapy. The American Cancer Society recommends regular CT scans, bronchoscopy, sputum cytology, thoracoscopy, and laboratory tests for NSCLC diagnosis and monitoring. With social distancing, online pharmacies and homecare have gained popularity. Smoking behaviors and air pollution continue to impact NSCLC expenditure on medications. Radiation oncologists, CT scans, deep learning systems, and Massachusetts General Hospital are pioneering advancements in NSCLC treatment. The pipeline includes multi-kinase inhibitors, mitotic inhibitors, antimetabolites, alkylating agents, and biologics.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio